NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Thursday that its fourth quarter revenues sank 24 percent as increases in laboratory services and collaboration revenues were offset by a decrease in product sales.

For the three months ended Dec. 31, the company reported total revenues of $1.0 million, down from $1.3 million in Q4 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.